Overview: GLB1 Gene Mutation TestIntroduction: The GLB1 Gene Mutation Test tests for GLB1 gene mutations to diagnose GM1 gangliosidosis or Morquio B disease, causing developmental delays or bone issues, aiding in diagnosis. Affecting 1 in 100,000 people, these conditions pose diagnostic challenges due to progressive symptoms. Following 2023 American College of Medical Genetics (ACMG) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, genetic counseling, and improving outcomes in pediatrics.
Other Names: GLB1 Mutation Test, Gangliosidosis Gene Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: Genetic testing for GM1 gangliosidosis began in the 1990s with research by O'Brien, who identified GLB1 mutations. PCR/sequencing advancements in the 2000s by Illumina improved detection, surpassing earlier enzymatic methods.
Purpose: Detects GLB1 mutations to diagnose GM1 gangliosidosis or Morquio B, guides supportive therapy, and evaluates patients with developmental delays, aiming to manage symptoms.
Test Parameters: GLB1 gene mutations
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of metabolic issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document developmental delay or bone issues. Include current medications or family history of genetic disorders.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., neurodegeneration), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutations confirm disease, guiding therapy. Early diagnosis might improve management, while untreated cases lead to death. Normal results may require enzyme assays.
Specialist Consultation: Consult a pediatrician or genetic counselor for interpretation.
Additional Supporting Tests: Enzyme activity test, MRI, or genetic panel to confirm diagnosis.
Test Limitations: Specific to GLB1 gene; correlation with symptoms needed. False negatives possible with untested variants.
References: ACMG Guidelines, 2023; Journal of Inherited Metabolic Disease, O'Brien JS, 2022.
